Hans Garmo

List of Publications by Year
in descending order

152 papers	4,637 citations	87723 38 h-index	123241 61 g-index
155 all docs	155 docs citations	155 times ranked	6929 citing authors

#	Article	IF	Citations
1	Radical Prostatectomy or Watchful Waiting in Prostate Cancer â€" 29-Year Follow-up. New England Journal of Medicine, 2018, 379, 2319-2329.	13.9	338
2	Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1243-1251.	0.8	225
3	Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology, 2013, 42, 956-967.	0.9	194
4	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. Journal of Clinical Oncology, 2014, 32, 3613-3618.	0.8	184
5	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. Journal of Clinical Oncology, 2010, 28, 3448-3456.	0.8	173
6	Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden. Journal of Urology, 2011, 185, 833-840.	0.2	104
7	Prostate cancer risk in the Swedish AMORIS study. Cancer, 2011, 117, 2086-2095.	2.0	87
8	Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology, 2020, 77, 180-188.	0.9	87
9	Anabolic steroids and cardiovascular risk: A national population-based cohort study. Drug and Alcohol Dependence, 2015, 152, 87-92.	1.6	86
10	Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2014, 192, 1116-1122.	0.2	84
11	Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons â€" the Swedish AMORIS study. European Journal of Cancer, 2011, 47, 2033-2041.	1.3	83
12	Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143.	1.1	82
13	Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes and Control, 2011, 22, 1163-1171.	0.8	81
14	Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Baseâ€"a refined prostate cancer trajectory. International Journal of Epidemiology, 2016, 45, 73-82.	0.9	78
15	Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. JAMA - Journal of the American Medical Association, 2015, 313, 2449.	3.8	76
16	The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. Radiation Oncology, 2019, 14, 40.	1.2	74
17	Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2016, 108, djw110.	3.0	69
18	The Metabolic Syndrome and the Risk of Prostate Cancer under Competing Risks of Death from Other Causes. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2088-2096.	1.1	68

#	Article	IF	Citations
19	Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. Journal of Cancer Epidemiology, 2012, 2012, 1-10.	0.5	67
20	Serum lactate dehydrogenase and survival following cancer diagnosis. British Journal of Cancer, 2015, 113, 1389-1396.	2.9	66
21	Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. European Urology, 2011, 60, 554-563.	0.9	65
22	Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2011, 22, 1011-1019.	0.8	63
23	Serum inflammatory markers and colorectal cancer risk and survival. British Journal of Cancer, 2017, 116, 1358-1365.	2.9	61
24	Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study. Atherosclerosis, 2016, 251, 85-93.	0.4	56
25	PCBaSe Sweden: A register-based resource for prostate cancer research. Scandinavian Journal of Urology and Nephrology, 2009, 43, 342-349.	1.4	54
26	The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort. International Journal of Cancer, 2017, 141, 1148-1160.	2.3	53
27	Association between Levels of C-Reactive Protein and Leukocytes and Cancer: Three Repeated Measurements in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 428-437.	1.1	52
28	Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. European Journal of Cancer, 2012, 48, 75-84.	1.3	52
29	Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes and Control, 2013, 24, 1393-1402.	0.8	51
30	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control, 2010, 21, 1657-1667.	0.8	49
31	The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. International Journal of Cancer, 2012, 130, 2118-2128.	2.3	47
32	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. International Journal of Cancer, 2017, 140, 611-617.	2.3	47
33	Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Population–Based Study. Journal of Clinical Oncology, 2012, 30, 3478-3485.	0.8	46
34	Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Medicine, 2016, 5, 1307-1318.	1.3	46
35	Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncológica, 2013, 52, 1593-1601.	0.8	44
36	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open, 2017, 7, e016606.	0.8	44

#	Article	IF	Citations
37	Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis, 2015, 36, 1121-1128.	1.3	43
38	Causes of death in men with localized prostate cancer: a nationwide, population‐based study. BJU International, 2016, 117, 507-514.	1.3	43
39	Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Research, 2016, 18, 119.	2.2	40
40	Risk of prostate cancer is not associated with levels of C‐reactive protein and other commonly used markers of inflammation. International Journal of Cancer, 2011, 129, 1485-1492.	2.3	39
41	Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Research and Treatment, 2011, 130, 609-618.	1.1	37
42	Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget, 2017, 8, 42332-42342.	0.8	37
43	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology, 2018, 73, 502-511.	0.9	37
44	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. OncoImmunology, 2016, 5, e1154250.	2.1	34
45	Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. Journal of Urology, 2017, 197, 61-66.	0.2	34
46	Radiation dose distribution in coronary arteries in breast cancer radiotherapy. Acta OncolÃ³gica, 2016, 55, 959-963.	0.8	31
47	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer, 2019, 19, 858.	1.1	30
48	Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. International Journal of Cancer, 2016, 139, 2698-2704.	2.3	29
49	Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. Breast Cancer Research, 2020, 22, 10.	2.2	29
50	Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies. International Journal of Molecular Sciences, 2016, 17, 1487.	1.8	28
51	Incidence of Second Malignancies for Prostate Cancer. PLoS ONE, 2014, 9, e102596.	1.1	27
52	Inter-observer variation in delineating the coronary arteries as organs at risk. Radiotherapy and Oncology, 2017, 122, 72-78.	0.3	27
53	Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health, 2013, 13, 663.	1.2	26
54	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26

#	Article	IF	Citations
55	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 66-76.	0.4	24
56	Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU International, 2016, 118, 391-398.	1.3	23
57	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS ONE, 2020, 15, e0228447.	1.1	23
58	Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 2015, 15, 913.	1.1	22
59	Immediate versus delayed prostatectomy: Nationwide population-based study. Scandinavian Journal of Urology, 2016, 50, 246-254.	0.6	22
60	Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. European Urology, 2016, 70, 824-828.	0.9	22
61	Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 122-33.	0.4	22
62	Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2012, 23, 1349-1358.	0.8	21
63	Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 920-928.	0.9	21
64	Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 125-134.	0.9	21
65	A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience, 2018, 12, 802.	0.6	19
66	Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases. International Journal of Cancer, 2021, 148, 2203-2211.	2.3	19
67	An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts. Epidemiology, 2021, 32, 607-615.	1.2	19
68	Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Research and Treatment, 2016, 159, 293-303.	1.1	18
69	Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. British Journal of Cancer, 2016, 114, 88-95.	2.9	18
70	Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. Breast, 2021, 59, 157-164.	0.9	18
71	Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS ONE, 2021, 16, e0255966.	1.1	18
72	Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study. European Journal of Cancer, 2014, 50, 1789-1798.	1.3	17

#	Article	IF	Citations
73	Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. European Urology, 2017, 72, 534-541.	0.9	17
74	Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncológica, 2016, 55, 1461-1466.	0.8	16
75	Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study. European Urology Oncology, 2018, 1, 37-45.	2.6	16
76	Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort. Cancer Causes and Control, 2019, 30, 603-615.	0.8	15
77	The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Annals of Surgical Oncology, 2017, 24, 1214-1220.	0.7	14
78	Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes and Control, 2019, 30, 195-206.	0.8	14
79	Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (<scp>SPCG</scp>â€4) study. BJU International, 2019, 123, 421-428.	1.3	14
80	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	2.0	14
81	Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. International Journal of Cancer, 2016, 138, 2154-2160.	2.3	13
82	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia Research, 2018, 74, 105-109.	0.4	13
83	Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer, 2017, 17, 246.	1.1	12
84	Survival after radiotherapy versus radical cystectomy for primary muscleâ€invasive bladder cancer: A Swedish nationwide populationâ€based cohort study. Cancer Medicine, 2019, 8, 2196-2204.	1.3	12
85	Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology, 2019, 75, 676-683.	0.9	12
86	Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based study. Acta Oncológica, 2020, 59, 106-111.	0.8	12
87	Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, populationâ€based study in Sweden. BJU International, 2020, 126, 142-151.	1.3	12
88	Prescription-based prediction of baseline mortality risk among older men. PLoS ONE, 2020, 15, e0241439.	1.1	12
89	Mortality in men with castrationâ€resistant prostate cancerâ€"A longâ€term followâ€up of a populationâ€based realâ€world cohort. BJUI Compass, 2022, 3, 173-183.	0.7	12
90	How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Medical Informatics and Decision Making, 2015, 15, 96.	1.5	11

#	Article	IF	Citations
91	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology, 2020, 54, 20-26.	0.6	11
92	Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998â€"2016. Acta OncolÃ³gica, 2020, 59, 549-557.	0.8	11
93	The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. European Journal of Cancer, 2018, 88, 101-108.	1.3	10
94	PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing. Scandinavian Journal of Urology, 2020, 54, 376-381.	0.6	10
95	Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer, 2020, 20, 551.	1.1	10
96	Risk of primary lung cancer after adjuvant radiotherapy in breast cancerâ€"a large population-based study. Npj Breast Cancer, 2021, 7, 71.	2.3	10
97	Interpretation of conventional survival analysis and competingâ€'risk analysis: an example of hypertension and prostate cancer. BJU International, 2016, 118, 850-852.	1.3	9
98	Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1026-1031.	0.4	9
99	Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Research, 2017, 19, 22.	2.2	9
100	H eterogeneity in risk of prostate cancer: A S wedish populationâ€'based cohort study of competing risks and T ype 2 diabetes mellitus. International Journal of Cancer, 2018, 143, 1868-1875.	2.3	9
101	Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer, 2019, 19, 612.	1.1	9
102	Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scandinavian Journal of Urology, 2022, 56, 104-111.	0.6	9
103	Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open, 2018, 8, e020787.	0.8	8
104	5Î±-Reductase Inhibitors and Risk of Prostate Cancer Death. Journal of Urology, 2020, 204, 714-719.	0.2	8
105	Risk of Fractures and Falls during and after 5-Î± Reductase Inhibitor Use: A Nationwide Cohort Study. PLoS ONE, 2015, 10, e0140598.	1.1	8
106	Observational study on time on treatment with abiraterone and enzalutamide. PLoS ONE, 2020, 15, e0244462.	1.1	8
107	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making, 2022, 22, 35.	1.5	8
108	No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis. International Journal of Cancer, 2020, 147, 76-83.	2.3	7

#	ARTICLE	IF	CITATIONS
109	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in Oncology, 2020, 10, 263.	1.3	7
110	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta OncolÃ³gica, 2021, 60, 459-465.	0.8	7
111	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunology, 2021, 22, 61.	0.9	7
112	Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget, 2018, 9, 774-782.	0.8	7
113	Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. Ecancermedicalscience, 2017, 11, 762.	0.6	6
114	Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scandinavian Journal of Urology, 2020, 54, 208-214.	0.6	6
115	The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. Cancers, 2021, 13, 875.	1.7	6
116	A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS ONE, 2018, 13, e0195690.	1.1	6
117	An investigation into the relationship between statins and cancer using population-based data. BJU International, 2015, 116, 681-683.	1.3	5
118	Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?. BMC Cancer, 2018, 18, 1169.	1.1	5
119	Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study. JNCI Cancer Spectrum, 2020, 4, pkaa006.	1.4	5
120	Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scandinavian Journal of Urology, 2021, 55, 221-226.	0.6	5
121	Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort. JAMA Network Open, 2021, 4, e219444.	2.8	5
122	Association between type 2 diabetes, curative treatment and survival in men with intermediateâ€•and highâ€•risk localized prostate cancer. BJU International, 2018, 121, 209-216.	1.3	4
123	Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis. BMC Molecular and Cell Biology, 2019, 20, 28.	1.0	4
124	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta OncolÃ³gica, 2019, 58, 110-118.	0.8	4
125	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	1.3	4
126	Simulation model of disease incidence driven by diagnostic activity. Statistics in Medicine, 2021, 40, 1172-1188.	0.8	4

#	Article	IF	Citations
127	Drugs for metabolic conditions and prostate cancer death in men on Gn<scp>RH</scp> agonists. BJU International, 2018, 121, 260-267.	1.3	3
128	Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer, 2018, 18, 205.	1.1	3
129	How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Medical Informatics and Decision Making, 2019, 19, 103.	1.5	3
130	Realâ€world insights into risk of developing cardiovascular disease following Gn<scp>RH</scp> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundamental and Clinical Pharmacology, 2019, 33, 479-499.	1.0	3
131	A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS ONE, 2021, 16, e0255239.	1.1	3
132	Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta OncolÃ³gica, 2021, 60, 1589-1596.	0.8	3
133	Data Resource Profile: Breast Cancer Data Base Sweden (BCBaSe 2.0). International Journal of Epidemiology, 2021, , .	0.9	3
134	Time on treatment with abiraterone in men with <i>de novo</i> metastatic castration sensitive prostate cancer: a drug utilization study. Acta OncolÃ³gica, 2022, 61, 328-332.	0.8	3
135	Satisfaction with Nurse-led Follow-up in Prostate Cancer Patientsâ€"A Nationwide Population-based Study. European Urology Open Science, 2022, 38, 25-31.	0.2	2
136	Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer. Seminars in Oncology Nursing, 2022, 38, 151236.	0.7	2
137	Susceptibility to <scp>SARSâ€Cov</scp>â€2 infection and risk for severe <scp>COVID</scp>â€19 in patients with prostate cancer on androgen deprivation therapy. International Journal of Cancer, 2022, 151, 1925-1934.	2.3	2
138	Temporal changes in causeâ€specific death in men with localised prostate cancer treated with radical prostatectomy: a populationâ€based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	0.8	1
139	Dietary Patterns and prostate cancer risk: a population based cohort study in elderly Swedish men. FASEB Journal, 2013, 27, 847.8.	0.2	1
140	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer, 2021, 21, 1259.	1.1	1
141	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology, 2022, 56, 169-175.	0.6	1
142	Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56â€"61. European Urology, 2017, 71, e61-e62.	0.9	0
143	Determinants of non-adherence to adjuvant endocrine treatment in early stage breast cancer patients: A Swedish population-based registry linkage study.. Journal of Clinical Oncology, 2016, 34, 535-535.	0.8	0
144	Abstract P3-20-02: The association of clinicopathological variables and patientÂ´s preference with surgical decision-making for early breast cancer. Cancer Research, 2022, 82, P3-20-02-P3-20-02.	0.4	0

#	Article	IF	Citations
145	Title is missing!. , 2020, 15, e0228447.		0
146	Title is missing!. , 2020, 15, e0228447.		0
147	Title is missing!. , 2020, 15, e0228447.		0
148	Title is missing!. , 2020, 15, e0228447.		0
149	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
150	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
151	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0
152	Prescription-based prediction of baseline mortality risk among older men. , 2020, 15, e0241439.		0